Basilea Pharmaceutica Ag Stock Performance
| BPMUF Stock | USD 52.83 0.00 0.00% |
Basilea Pharmaceutica has a performance score of 9 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.0268, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Basilea Pharmaceutica's returns are expected to increase less than the market. However, during the bear market, the loss of holding Basilea Pharmaceutica is expected to be smaller as well. Basilea Pharmaceutica right now shows a risk of 0.39%. Please confirm Basilea Pharmaceutica information ratio and rate of daily change , to decide if Basilea Pharmaceutica will be following its price patterns.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Basilea Pharmaceutica AG are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable basic indicators, Basilea Pharmaceutica is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 66.3 M | |
| Total Cashflows From Investing Activities | 3.6 M | |
| Free Cash Flow | -32.9 M |
Basilea |
Basilea Pharmaceutica Relative Risk vs. Return Landscape
If you would invest 5,126 in Basilea Pharmaceutica AG on September 1, 2024 and sell it today you would earn a total of 157.00 from holding Basilea Pharmaceutica AG or generate 3.06% return on investment over 90 days. Basilea Pharmaceutica AG is currently producing 0.0486% returns and takes up 0.3859% volatility of returns over 90 trading days. Put another way, 3% of traded pink sheets are less volatile than Basilea, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Basilea Pharmaceutica Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Basilea Pharmaceutica's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Basilea Pharmaceutica AG, and traders can use it to determine the average amount a Basilea Pharmaceutica's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.126
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BPMUF |
Estimated Market Risk
| 0.39 actual daily | 3 97% of assets are more volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 9 91% of assets perform better |
Based on monthly moving average Basilea Pharmaceutica is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Basilea Pharmaceutica by adding it to a well-diversified portfolio.
Basilea Pharmaceutica Fundamentals Growth
Basilea Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Basilea Pharmaceutica, and Basilea Pharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Basilea Pink Sheet performance.
| Return On Asset | 0.0261 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 724.26 M | |||
| Shares Outstanding | 11.93 M | |||
| Price To Earning | 200.00 X | |||
| Price To Sales | 4.09 X | |||
| Revenue | 148.12 M | |||
| EBITDA | 2.11 M | |||
| Cash And Equivalents | 140.74 M | |||
| Cash Per Share | 11.89 X | |||
| Total Debt | 94.54 M | |||
| Book Value Per Share | (5.67) X | |||
| Cash Flow From Operations | (32.02 M) | |||
| Earnings Per Share | 0.25 X | |||
| Total Asset | 247.27 M | |||
| Retained Earnings | (908 M) | |||
| Current Asset | 283 M | |||
| Current Liabilities | 64 M | |||
About Basilea Pharmaceutica Performance
By analyzing Basilea Pharmaceutica's fundamental ratios, stakeholders can gain valuable insights into Basilea Pharmaceutica's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Basilea Pharmaceutica has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Basilea Pharmaceutica has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland. BASILEA PHARMACEUTICA is traded on OTC Exchange in the United States.Things to note about Basilea Pharmaceutica performance evaluation
Checking the ongoing alerts about Basilea Pharmaceutica for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Basilea Pharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 148.12 M. Net Loss for the year was (6.83 M) with profit before overhead, payroll, taxes, and interest of 30.89 M. | |
| Basilea Pharmaceutica AG has accumulated about 140.74 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 11.89. |
- Analyzing Basilea Pharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Basilea Pharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Basilea Pharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Basilea Pharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Basilea Pharmaceutica's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Basilea Pharmaceutica's pink sheet. These opinions can provide insight into Basilea Pharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Basilea Pink Sheet analysis
When running Basilea Pharmaceutica's price analysis, check to measure Basilea Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Basilea Pharmaceutica is operating at the current time. Most of Basilea Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Basilea Pharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Basilea Pharmaceutica's price. Additionally, you may evaluate how the addition of Basilea Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |